Skip to content

Twitter page opens in new window Linkedin page opens in new window Instagram page opens in new window

investorenquiries@pharmaust.com+61 8 9202 6814

PharmAust (PAA)

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

HOME
ABOUT
PIPELINE & TRIALS
INVESTOR CENTRE
MEDIA
CONTACT

Sept 10, PharmAust Broker Briefing Presentation

210909_Broker Briefing_PAA

Category: News and Announcements 2021By PharmAust September 9, 2021

Related posts

December 15, Epichem Awarded DNDi Extension
December 15, 2021

December 13, Shareholder Update and Strategy
December 13, 2021

December 1, Demonstration Batch Small MPL Tablets Completed
December 1, 2021

December 1, Top 20 Shareholders
December 1, 2021

November 17, FightMND and COVID-19 Trials on Track
November 17, 2021

November 15, New Zealand Joins Phase 2B Pet Dog Trial
November 15, 2021

Recent Articles

Canine Cancer Trial Update
March 27, 2023
Free Biotech & Nutrition Investor Webinar
March 17, 2023
First Patient of Cohort 2 Dosed in MND Trial 3 market sensitive
February 20, 2023
PharmAust canine trial update 18 market sensitive
February 10, 2023

MENU

Home
About Us
Pipeline & Trials
Investor Centre
Media
Contact Us

SUBSCRIBE TO OUR NEWSLETTER

Leave this field empty if you're human:

TWITTER

PharmAust Follow

PharmAust is a clinical-stage biotech company developing drug discovery IP to treat cancer, viral and neurological diseases. ASX: $PAA FSE: $ECQ

PharmAust @pharmaust ·

14h

PharmAust (ASX:PAA) completes enrolment of second patient cohort in MND/ALS trial https://themarketherald.com.au/pharmaust-asxpaa-completes-enrolment-of-second-patient-cohort-in-mnd-als-trial-2023-03-30/ via @themarketherald

Reply on Twitter 1641338317286543360 Retweet on Twitter 1641338317286543360 2 Like on Twitter 1641338317286543360 11 Twitter 1641338317286543360

PharmAust @pharmaust ·

18h

PharmAust completes patient enrolment for MPL trial with sights on US$3.6 billion Motor Neurone Disease market

https://stockhead.com.au/health/pharmaust-completes-patient-enrolment-for-mpl-trial-with-sights-on-us3-6-billion-motor-neurone-disease-market/

Reply on Twitter 1641272193236758529 Retweet on Twitter 1641272193236758529 4 Like on Twitter 1641272193236758529 14 Twitter 1641272193236758529

PharmAust @pharmaust ·

20h

Pandemic Pet Adoptions Propel Rise of a $500 Billion Global Market
Via ⁦@Bloomberg⁩ https://www.bloomberg.com/news/articles/2023-03-24/pet-industry-outlook-is-strong-despite-rising-costs-of-food-vet-care

Reply on Twitter 1641241590726561792 Retweet on Twitter 1641241590726561792 3 Like on Twitter 1641241590726561792 8 Twitter 1641241590726561792

Load More

Copyright © 2023 PharmAust. All rights reserved.

nil

Website Design & Digital Marketing Perth by Total Click Solutions